7 matches for your search in the start-up spotlight
rss
16-Sep-2024
PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...
New hope in the fight against unmet diseases
15-Dec-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, announced a strategic research partnership aimed at advancing modern phenotypic drug ...
PhoreMost to deploy its SITESEEKER Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets
03-Nov-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will ...
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes
07-Sep-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for ...
19-Jan-2022
NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...
Start-ups combine biotechnology and artificial intelligence
06-Jan-2022
PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...
Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing
25-Mar-2021
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...
